Core Viewpoint - The company has approved the use of up to 450 million yuan of idle funds for cash management, aiming to enhance fund efficiency and provide reasonable returns for shareholders [1][6]. Group 1: Cash Management Product Purchase - The company plans to invest in cash management products issued by commercial banks and other institutions, with a maximum investment limit of 450 million yuan [1]. - The investment products will include high-security, liquid options such as bank time deposits, structured deposits, and agreement deposits, with individual product investment periods not exceeding 12 months [1]. - As of the announcement date, the company has no outstanding cash management products purchased with its own funds within the last twelve months [5]. Group 2: Risk Analysis - Market risks may affect the market value of the invested assets, potentially leading to early termination of the cash management products [2]. - Liquidity risks exist as these products do not allow for redemption outside of specified periods, meaning investors cannot terminate early [2]. - Credit risks could arise if the issuer faces bankruptcy or other credit issues, impacting the principal and returns of the cash management products [2]. - Policy risks may affect the normal operation of these products if there are changes in national macro policies or relevant regulations [2]. - Interest rate risks are present, as fluctuations may lead to lower effective returns compared to inflation [2]. Group 3: Risk Mitigation Measures - The company's finance department will monitor the recovery of principal and returns from cash management products and take protective measures if risks are identified [4]. - The internal audit department will oversee the use and custody of funds related to the purchased cash management products and report to the board's audit committee [4]. - Independent directors and the supervisory board have the right to conduct regular or irregular checks on the investment status of cash management products [4]. Group 4: Impact on the Company - The purchase of cash management products will not affect the company's normal cash flow or the operation of its main business [5]. - The cash management initiative is expected to improve fund utilization efficiency and create reasonable returns for the company and its shareholders [5].

Core Viewpoint - The company, Jinfa Labi, is undergoing a board of directors' re-election process, with the sixth board set to be elected at the upcoming extraordinary shareholders' meeting scheduled for December 16, 2025 [25][26]. Group 1: Board Meeting and Resolutions - The fifth board of directors held its 23rd meeting on November 27, 2025, where it approved the proposal for the re-election of the board [2][3]. - The proposal for convening the fourth extraordinary shareholders' meeting in 2025 was also approved, with a unanimous vote of 7 in favor [4][5]. Group 2: Shareholders' Meeting Details - The extraordinary shareholders' meeting will take place on December 16, 2025, with both on-site and online voting options available [9][10]. - The record date for shareholders to attend the meeting is set for December 8, 2025 [10]. Group 3: Board Composition and Candidate Information - The sixth board will consist of 7 members, including 3 non-independent directors, 3 independent directors, and 1 employee representative [25]. - The candidates for the sixth board include Lin Guodong, Tang Dianqin, and Lin Guixian as non-independent directors, and Li Shengping, Gu Debin, and Fu Yumei as independent directors [26][27]. Group 4: Candidate Qualifications - All nominated candidates have been reviewed and deemed qualified according to relevant laws and regulations, with no disqualifying factors identified [26][32]. - The independent directors' qualifications will require approval from the Shenzhen Stock Exchange before being submitted for shareholder voting [26].

Group 1 - The company, Jinfa Labi, expects a significant increase in revenue for the first half of 2025, projecting an estimated revenue of 78.26 million yuan, representing a growth of 104.45% to 117.23% compared to the same period last year [1] - The company anticipates a net loss attributable to shareholders ranging from 8 million to 16 million yuan, which is a decline of 190.50% to 481.00% compared to a loss of 2.75 million yuan in the previous year [1] - The basic earnings per share are expected to be a loss of 0.02 to 0.05 yuan per share, compared to a loss of 0.01 yuan per share in the same period last year [1] Group 2 - The company reported that its outpatient department generated approximately 33 million yuan in revenue for the first half of 2025, indicating a substantial increase [1] - Despite a significant reduction in losses from its investment company, the company still faces some level of loss, which must be recognized according to its shareholding ratio [1] - The company has upgraded its IP image, which is gradually being applied to products and packaging, and is accelerating the promotion of old products to recover funds [1]